02.02.2016 - Forecasts on revenue of Pfizer have led to a deterioration in investor expectations

Pharmaceutical giant Pfizer has reported on the results in the 4th quarter of last year. Thus, profit fell to 613 million dollars against 1.228 billion dollars in the same period in 2014. At the same time, revenue rose to 14.05 billion against the forecast of 13.58 billion. Negative factor was the reduction in forecast of revenue for 2016 year to 49-51 billion dollars against the previous estimates at 53 billion. We expect a decrease in quotations in the near future.

RISK WARNING: Trading of complex financial products, such as Stocks, Futures, Foreign Exchange ("Forex"), Contracts for Difference ("CFDs"), Indices, Options, or other financial derivatives, on "margin" carries a high level of risk, and may not be suitable for all investors. The possibility exists that you could sustain a loss of some or all of your initial investment and, therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading these markets, and seek advice from an independent financial advisor if you have any questions or doubts. Please carefully read our full "Risk Disclosure" and "Risk Disclosures for Financial Instruments & Investment Services". FXFINPRO Capital is the trading name of PFX Financial Professionals Limited, a limited liability company formed under the laws of Cyprus, registered with the Registrar of Companies in Nicosia, Cyprus, under nr. HE 237840 and regulated by the Cyprus Securities and Exchange Commission with license number 193/13.